<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050553</url>
  </required_header>
  <id_info>
    <org_study_id>17222</org_study_id>
    <secondary_id>I8F-MC-GPHG</secondary_id>
    <secondary_id>2019-001360-29</secondary_id>
    <nct_id>NCT04050553</nct_id>
  </id_info>
  <brief_title>A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Crossover Study to Investigate the Effect of Once-Weekly Tirzepatide on the Counter-Regulatory Response to Hypoglycemia in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to learn more about how tirzepatide affects the body's&#xD;
      response to low blood sugar (hypoglycemia). The study is open to participants with type 2&#xD;
      diabetes. It will last about 42 weeks for each participant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">February 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 16, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Glucagon Concentration During Induced Hypoglycemia from Target Plasma Glucose (PG) Concentration of 100 Milligrams per Deciliter (mg/dL) to a Nadir Target of 45 mg/dL</measure>
    <time_frame>Week 12 in each study period: Baseline and up to 30 minutes after reaching the nadir glucose level</time_frame>
    <description>Change in Mean Glucagon Concentration During Induced Hypoglycemia from Target PG Concentration of 100 mg/dL to a Nadir Target of 45 mg/dL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Insulin Concentrations from Induced Hypoglycemia Target PG Concentration of 100 mg/dL to a Nadir Target of 45 mg/dL</measure>
    <time_frame>Week 12 in each study period: Baseline and up to 30 minutes after reaching the nadir glucose</time_frame>
    <description>Change in Mean Insulin Concentrations from Induced Hypoglycemia Target PG Concentration of 100 mg/dL to a Nadir Target of 45 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean C-peptide Concentrations from Induced Hypoglycemia Target PG Concentration of 100 mg/dL to a Nadir Target of 45 mg/dL</measure>
    <time_frame>Week 12 in each study period: Baseline and up to 30 minutes after reaching the nadir glucose</time_frame>
    <description>Change in Mean C-peptide Concentrations from Induced Hypoglycemia Target PG Concentration of 100 mg/dL to a Nadir Target of 45 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from Termination of Insulin Infusion at PG Concentration of 45 mg/dL to Reach Recovery PG Concentration (72 mg/dL)</measure>
    <time_frame>Week 12 in each treatment period (treatment period = 12 weeks): 1 minute after reaching the nadir glucose level and when reaching normoglycemia (estimated as 30 mins)</time_frame>
    <description>Time from Termination of Insulin Infusion at PG Concentration of 45 mg/dL to Reach Recovery PG Concentration (72 mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia Symptoms Score from Induced Hypoglycemia at Target PG Concentrations of 100 mg/dL, 63 mg/dL, 45 mg/dL and Recovery (PG Concentration 72 mg/dL)</measure>
    <time_frame>Week 12 in each treatment period (treatment period = 12 weeks): 1 minute after reaching the nadir glucose level and when reaching normoglycemia (estimated as 30 mins)</time_frame>
    <description>Hypoglycemia Symptoms Score from Induced Hypoglycemia at Target PG Concentrations of 100 mg/dL, 63 mg/dL, 45 mg/dL and Recovery (PG Concentration 72 mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Blood Pressure from Induced Hypoglycemia Target PG Nadir Concentration of 100 mg/dL to a Nadir Target of 45 mg/dL</measure>
    <time_frame>Week 12 in each study period: Baseline and up to 30 minutes after reaching the nadir glucose</time_frame>
    <description>Mean Change in Blood Pressure from Induced Hypoglycemia Target PG Nadir Concentration of 100 mg/dL to a Nadir Target of 45 mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Heart Rate from Induced Hypoglycemia Target PG Concentration of 100 mg/dL to a Nadir Target of 45 mg/dL</measure>
    <time_frame>Week 12 in each study period: Baseline and up to 30 minutes after reaching the nadir glucose</time_frame>
    <description>Mean Change in Heart Rate from Induced Hypoglycemia Target PG Concentration of 100 mg/dL to a Nadir Target of 45 mg/dL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Tirzepatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tirzepatide administered subcutaneously (SC) in one of two study periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC in one of two study periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Tirzepatide</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have type 2 diabetes mellitus (T2DM) for at least 1 year&#xD;
&#xD;
          -  Treated with diet and exercise and stable dose(s) of metformin 3 months prior to study&#xD;
             entry with or without 1 additional oral antidiabetic medication (OAM) other than&#xD;
             metformin.&#xD;
&#xD;
          -  Have a hemoglobin A1c (HbA1c) value at screening of ≥6.5% and ≤9.0 % if on metformin&#xD;
             only.&#xD;
&#xD;
          -  Have a HbA1c value at screening of ≥6.0% and ≤8.5 %, if on metformin and 1 more&#xD;
             allowed OAM.&#xD;
&#xD;
          -  Have a body mass index (BMI) between 23 and 45 kilograms per square meter (kg/m²)&#xD;
             inclusive, at screening&#xD;
&#xD;
          -  Are of stable weight (±5%) &gt;3 months prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history of proliferative retinopathy or maculopathy as determined by the&#xD;
             investigator based on a recent (&lt;6 months) ophthalmologic examination&#xD;
&#xD;
          -  Impaired renal estimated glomerular filtration rate (eGFR) &lt;60 milliliters per minute&#xD;
             per 1.73 square meters (mL/min/1.73 m²) calculated by Chronic Kidney Disease&#xD;
             Epidemiology Collaboration (CKD-EPI)&#xD;
&#xD;
          -  Have a history of or current cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal (GI), endocrine, hematological or neurological disorders capable of&#xD;
             significantly altering the absorption, metabolism or elimination of drugs; of&#xD;
             constituting a risk when taking the study drug; or of interfering with the&#xD;
             interpretation of data&#xD;
&#xD;
          -  Have had acute myocardial infarction, congestive heart failure New York Heart&#xD;
             Association Class III or IV, history of or suspected ischemic heart disease, and/or&#xD;
             cerebrovascular accident (stroke [including transient ischemic attack])&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 1, 2021</verification_date>
  <study_first_submitted>August 7, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirzepatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

